Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington\u27s disease knock-in mice. by Kovalenko, Marina et al.
Thomas Jefferson University
Jefferson Digital Commons
Faculty papers Farber Institute for Neurosciences Farber Institute for Neurosciences
1-1-2012
Msh2 acts in medium-spiny striatal neurons as an
enhancer of CAG instability and mutant huntingtin
phenotypes in Huntington's disease knock-in mice.
Marina Kovalenko
Massachusetts General Hospital
Ella Dragileva
Massachusetts General Hospital
Jason St Claire
Massachusetts General Hospital
Tammy Gillis
Massachusetts General Hospital
Jolene R Guide
Massachusetts General Hospital
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/farberneursofp
Part of the Medical Neurobiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Recommended Citation
Kovalenko, Marina; Dragileva, Ella; St Claire, Jason; Gillis, Tammy; Guide, Jolene R; New, Jaclyn;
Dong, Hualing; Kucherlapati, Raju; Kucherlapati, Melanie H; Ehrlich, Michelle E; Lee, Jong-Min;
and Wheeler, Vanessa C, "Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG
instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice." (2012).
Faculty papers Farber Institute for Neurosciences. Paper 11.
http://jdc.jefferson.edu/farberneursofp/11
Authors
Marina Kovalenko, Ella Dragileva, Jason St Claire, Tammy Gillis, Jolene R Guide, Jaclyn New, Hualing Dong,
Raju Kucherlapati, Melanie H Kucherlapati, Michelle E Ehrlich, Jong-Min Lee, and Vanessa C Wheeler
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/farberneursofp/11
Msh2 Acts in Medium-Spiny Striatal Neurons as an
Enhancer of CAG Instability and Mutant Huntingtin
Phenotypes in Huntington’s Disease Knock-In Mice
Marina Kovalenko1., Ella Dragileva1., Jason St. Claire1, Tammy Gillis1, Jolene R. Guide1, Jaclyn New1,
Hualing Dong1, Raju Kucherlapati2, Melanie H. Kucherlapati2, Michelle E. Ehrlich3, Jong-Min Lee1,
Vanessa C. Wheeler1*
1Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2Department of Medicine, Brigham and
Women’s Hospital, Boston, Massachusetts, United States of America, 3 Farber Institute for Neurosciences, Thomas Jefferson University College of Medicine, Philadelphia,
Pennsylvania, United States of America
Abstract
The CAG trinucleotide repeat mutation in the Huntington’s disease gene (HTT) exhibits age-dependent tissue-specific
expansion that correlates with disease onset in patients, implicating somatic expansion as a disease modifier and potential
therapeutic target. Somatic HTT CAG expansion is critically dependent on proteins in the mismatch repair (MMR) pathway.
To gain further insight into mechanisms of somatic expansion and the relationship of somatic expansion to the disease
process in selectively vulnerable MSNs we have crossed HTT CAG knock-in mice (HdhQ111) with mice carrying a conditional
(floxed) Msh2 allele and D9-Cre transgenic mice, in which Cre recombinase is expressed specifically in MSNs within the
striatum. Deletion of Msh2 in MSNs eliminated Msh2 protein in those neurons. We demonstrate that MSN-specific deletion
of Msh2 was sufficient to eliminate the vast majority of striatal HTT CAG expansions in HdhQ111 mice. Furthermore, MSN-
specific deletion of Msh2 modified two mutant huntingtin phenotypes: the early nuclear localization of diffusely
immunostaining mutant huntingtin was slowed; and the later development of intranuclear huntingtin inclusions was
dramatically inhibited. Therefore, Msh2 acts within MSNs as a genetic enhancer both of somatic HTT CAG expansions and of
HTT CAG-dependent phenotypes in mice. These data suggest that the selective vulnerability of MSNs may be at least in part
contributed by the propensity for somatic expansion in these neurons, and imply that intervening in the expansion process
is likely to have therapeutic benefit.
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Introduction
Huntington’s disease (HD) is a dominantly inherited neurode-
generative disorder characterized by motor, cognitive and
psychiatric symptoms [1]. The underlying cause is the expansion
.35 repeats of a polymorphic CAG repeat within HTT gene that
lengthens a glutamine tract in the huntingtin protein [2]. Stringent
statistical analyses in a large HD patient data set indicate that the
CAG expansion determines onset age in a fully dominant fashion
with no evidence for a major role of either the wild-type allele or
a second mutant allele [3]. While mutant huntingtin exerts its toxic
effects in many brain regions as well as peripheral tissues over the
course of the disease, medium-spiny GABA-ergic projection
neurons (MSNs) in the striatum are the most vulnerable [4–6].
Therefore, the factors that contribute to this neuronal susceptibil-
ity are likely to provide clues to pathogenesis. Despite being caused
by a single gene defect the disease is clearly complex, with
a multitude of cellular pathways disrupted in response to mutant
huntingtin [7]. Discerning those events that are critical to
pathogenesis in order to design rational therapeutics remains
a challenge.
An alternative to targeting downstream pathways that are
disrupted during the course of disease is to target the CAG repeat
mutation itself. Given that onset age and disease severity are highly
correlated with the length of the expanded CAG repeat [3,8], one
would predict that reducing CAG length, even within the disease
range, would have a beneficial effect. Notably, the mutant HTT
CAG repeat exhibits both intergenerational and somatic instability
[8–17]. The latter is highly biased towards expansions and is
tissue-specific, with the greatest expansions seen in the striatum
[13]. The striatum appears to be particularly susceptible to
expansion in several trinucleotide repeat diseases [18–20],
consistent with findings that expansion reflects an intrinsic
property of this tissue rather than being a consequence of ongoing
pathogenesis [21]. However, the further expansion of the mutant
HTT CAG repeat in the striatum as well in other tissues
susceptible to the effects of mutant huntingtin, is predicted to
contribute to the pathogenic process. Indeed, longer somatic
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expansions in HD postmortem brain correlate with an earlier age
of disease onset [17]. Therefore, the factors that modify repeat
instability are predicted to modify disease and may lead to novel
therapeutic targets.
To study the mechanisms underlying HTT CAG instability we
have developed a series of HTT homologue (Htt or Hdh) CAG
knock-in mice that replicate the genetic mutation in HD patients
[22,23]. Notably, these mice exhibit CAG length- and age-
dependent, tissue-specific somatic expansion, with amongst the
highest levels of instability seen in the striatum [21,23,24]. We
have previously shown that striatal instability in HdhQ111 mice is
critically dependent on mismatch repair genes Msh2 and Msh3
[25,26]. Significantly, constitutional knockout of either of these
two genes delayed an early, dominant, CAG length-dependent
phenotype in the striatum, the nuclear localization/epitope
accessibility of mutant huntingtin, supporting the hypothesis that
somatic expansions in target tissues contributes to the pathogenic
process [25,26].
Here, we sought to explore further the role of Msh2 as a genetic
modifier of HTT CAG repeat instability and pathogenesis. Given
the particular susceptibility of MSNs to the disease process we
have used a conditional knockout strategy to specifically delete the
Msh2 gene in this neuronal subtype of HdhQ111 mice. This
neuronal subtype-specific deletion of Msh2, allowed us to ask the
following questions: 1. Is Msh2 required in MSNs to mediate HTT
CAG expansion? 2. Is Msh2 required in MSNs as a modifier of
CAG repeat length-dependent mutant huntingtin localization and
intranuclear inclusion phenotypes?
Results
Conditional Deletion of Msh2 in Medium-spiny Striatal
Neurons
To delete the Msh2 gene we used a conditional Msh2 knockout
mouse line in which exon 12 that encodes part of Msh2’s essential
ATPase domain is flanked by loxP sites (Msh2flox) [27]. To achieve
specific deletion in MSNs we used a transgenic line (D9-Cre) in
which Cre recombinase is expressed under the control of
regulatory elements of the mouse Ppp1r1b gene encoding
DARPP-32 [28]. Within the striatum, D9-Cre mice have been
shown to express Cre specifically in MSNs from 5–6 weeks of age
[28]. Crossing the Msh2flox and D9-Cre mice together demonstrat-
ed deletion of exon 12 of the Msh2 gene in striatal DNA only in
Msh2flox mice that also harbored the D9-Cre transgene (Figure 1A).
Note that the undeleted (floxed) allele is still present in D9-Cre mice,
which likely reflects contributions both from non-MSNs (inter-
neurons and glia) that do not express the Cre transgene, and a small
number of MSNs in which Cre-mediated recombination does not
occur [28]. Comparison of genomic DNA isolated from different
tissues (striatum, cerebellum, cortex, liver, tail) from Msh2flox/+
D9-Cre mice showed that deletion of Msh2 exon 12 was specific to
the striatum (Figure 1B). The absence of Cre-mediated re-
combination in other tissues is consistent with the very low
number of cortical neurons and cerebellar purkinje cells in which
Cre activity was previously observed and the general absence of
recombination in peripheral tissues [28]. We will refer henceforth
to the conditionally MSN-deleted allele, present inMsh2flox D9-Cre
mice as Msh2D.
Msh2 Protein is Eliminated in Medium-spiny Striatal
Neurons
To examine the effect of MSN-specific deletion of Msh2 on
phenotypes elicited by an expanded HTT CAG repeat we
established crosses with HdhQ111 mice, Msh2flox mice, D9-Cre
mice and Msh2 null mice (Figure S1) to generate HdhQ111/+ mice
with the following five genotypes: Msh2+/+, Msh2+/2, Msh2D/D,
Msh2D/2 and Msh22/2, allowing us to compare directly the
effect of MSN-specific deletion of Msh2 and constitutional Msh2
deletion. Note that while 50% of Msh22/2 mice die by 6 months
of age due to tumor burden (largely in lymphatic tissue and the
gut) [29] we did not observe any reduced viability or brain tumors
in Msh2D/D or Msh2D/2 mice that were aged as far as 10
months.
We first determined the expression levels of Msh2 protein in
striatal extracts from mice with Msh2+/+, Msh2+/2, Msh2D/D,
Msh2D/2 and Msh22/2 genotypes. Msh2 protein levels were
reduced by ,60% in Msh2D/D and Msh2D/2 striatal extracts
compared those in Msh2+/+ and Msh2+/2 striatal extracts
(Figure 2A,B). To assess more precisely the level of knockdown
of Msh2 in MSNs we co-immunostained striatal sections with an
antibody against DARPP-32 that specifically labels MSNs and an
antibody against Msh2. This revealed the specific loss of Msh2 in
MSNs in Msh2D/D and Msh2D/2 mice (Figure 2C). Quantifica-
tion of the immunofluorescent images (Figure 2D) showed
significantly reduced levels of Msh2 in DARPP-32-positive MSNs
in Msh2D/D compared toMsh2+/+ mice (p,0.01) and inMsh2D/
2 compared toMsh2+/2 mice (p,0.01). There was no significant
difference in levels of Msh2 in MSNs between Msh2D/D or
Msh2D/2 and Msh22/2 mice, indicating the complete loss of
Msh2 in Msh2D/D and Msh2D/2 MSNs. Note that the Msh2
protein level in Msh2+/2 striata (Figure 2A, B) or MSNs
(Figure 2C, D) is greater than 50% of that in Msh2+/+ striata,
suggesting possible compensatory mechanisms, at least in striatal
tissues/cells, by which the cell is able to regulate Msh2 levels to
some degree.
Msh2 Acts in Medium-spiny Striatal Neurons to Effect HTT
CAG Expansion
To investigate the effect of MSN-specific Msh2 deletion on the
somatic instability of the HTT CAG repeat HdhQ111/+ mice with
Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2 and Msh22/2
genotypes were aged to five months of age, a time-point at which
we have previously observed significant accumulation of somatic
expansions in HdhQ111/+ striata. GeneMapper traces obtained
from PCR-amplification of the HTT CAG repeat (Figure 3A)
showed a bimodal distribution of CAG repeat lengths in striatal
DNA from both Msh2+/+ and Msh2+/2 mice, as previously
observed [26]. Also consistent with our previous studies of Msh2
null HdhQ111 mice [25], these somatic expansions were
completely eliminated in striatal DNA from Msh22/2 mice. In
striatal DNA from both Msh2D/2 and Msh2D/D mice the
somatically expanded repeats were dramatically reduced, although
not eliminated as in Msh22/2 mice. Quantification of the
GeneMapper traces (Figure 3B) revealed a significant reduction in
instability in striata from Msh2D/D compared to Msh2+/+ mice
(p,0.0001) and in striata from Msh2D/2 compared to Msh2+/2
mice (p,0.0001). As assayed using our quantification method,
there were no significant differences in striatal instability between
Msh2D/D and Msh22/2 mice (p = 0.18) or between Msh2D/2
and Msh22/2 mice (p = 0.33). Consistent with the tissue-specific
Msh2 deletion shown in Figure 1B, Msh2D/D and Msh2D/2 mice
did not show any alteration in instability in liver or cortex,
although instability in these tissues (high in liver and moderate in
cortex) was eliminated in Msh22/2 mice.
To determine whether elimination of Msh2 in MSNs was
sufficient to suppress somatic expansion over a more extensive
time-period, we examined instability in HdhQ111/+Msh2D/D and
HdhQ111/+ Msh2D/2 mice at ten months of age. While ten-
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month Msh2+/+ and Msh2+/2 striata (Figure 3C, D) showed
increased levels of instability compared to those at five months of
age (Figure 3A, B), no obvious instability was apparent in either
Msh2D/D or Msh2D/2 striata at ten months (Figure 3C).
Quantification (Figure 3D) revealed a significant difference in
instability between Msh2+/2 and Msh2D/2 striata (p,0.0001).
As there was only a singleMsh2D/D at this age we were not able to
perform any statistical analyses and it is formally possible that
Msh2D/D mice may exhibit a wide variation in phenotype that is
not apparent from the analysis of a single mouse (see also
subsequent Results section). However, the essentially identical
findings for this mouse compared to the seven Msh2D/2 mice at
the same age supports the conclusion that loss of Msh2 in MSNs
reduces instability. It is likely that at ten months of age the signal
from the residual small population of unstable CAG repeats in
Msh2D/D and Msh2D/2 striata is too diffuse to be readily
discernible and quantifiable by our method. Thus, it appears that
while the residual unstable molecules likely continue to expand,
the molecules stable at five months of age retain their stability at
ten months of age in Msh2D/D and Msh2D/2 striata. These data
indicate that the majority of the HTT CAG striatal expansions
occur in MSNs and that Msh2 expression within these neurons is
critical to the expansion process over a period of at least ten
months.
Msh2 Acts in Medium-spiny Striatal Neurons as an
Enhancer of the HTT CAG Repeat Length-Dependent
Phenotypes
Previous data in HD patients and HdhQ111 mice are consistent
with the hypothesis that somatic expansions accelerate the HTT
CAG-dependent pathogenic process [17,25]. We have identified
two CAG repeat-length dependent phenotypes in knock-in mice
that would be predicted to be altered as a result of the loss of
somatically expanded HTT CAG repeats; early (,2.5 months)
diffusely-immunostaining nuclear mutant huntingtin using the
anti-huntingtin antibody EM48 and later (6–12 months) intra-
nuclear inclusions of mutant huntingtin amino-terminal fragments
[30–32]. While the direct consequences to the cell of either of
these phenotypes are unclear, the observation that they are
dominant, CAG repeat length-dependent and occur with a strong
selectivity towards MSNs [30,31] indicates that their underlying
mechanisms are likely to be relevant to the pathogenic process in
HD. Given the critical role of Msh2 in mediating somatic
expansion in MSNs we have tested whetherMsh2 is also a modifier
of these two CAG length-dependent mutant huntingtin pheno-
types. We previously showed that constitutional loss of Msh2
slowed the diffuse nuclear huntingtin phenotype in the striatum
[25]. We have now developed a modified, quantitative assay to
measure the time-dependent increase in diffuse nuclear mutant
huntingtin in HdhQ111/+ mice using the anti-huntingtin mono-
clonal antibody mAb5374 (Figure S2). We have used this assay to
determine the role played by MSN-expressed Msh2 in de-
termining the diffuse nuclear mutant huntingtin phenotype. In
our previous study [25] we did not analyze the effect of the Msh2
null mutation on nuclear inclusions in HdhQ111 mice as the
reduced lifespan of the Msh2 null mice precluded our ability to
analyze this phenotype that was not apparent until ,12 months
on the genetic background of the original HdhQ111 x Msh2 null
cross (mixed CD1/129Ola/FVB). Here, afforded by the earlier
appearance of intranuclear inclusions on C57BL/6 backgrounds
[32] we have also asked whether MSN-expressed Msh2 is
a modifier of intranuclear inclusions.
Striatal sections from the same five-month and ten-month mice
in which we determined somatic instability (Figure 3) were
immunostained with mAb5374 (Figure 4). mAb5374 staining in
five-month mice was found to depend both on the constitutive
CAG repeat length as well as the position (medial versus lateral)
within the striatum, with longer CAG lengths and lateral location
resulting in increased staining (p,0.05 and p,0.001, respectively).
Therefore, to determine the effect of Msh2 genotype on mAb5374
staining we performed a multiple regression analysis, controlling
for both constitutive CAG length and lateral versus medial
position in the striatum. We found that, compared to Msh2+/+
mice, mAb5374 staining was reduced in both Msh2D/D (p,0.01)
and Msh2D/2 (p,0.001) mice as well as in Msh22/2 mice as
predicted (p,0.05) (Figure 4A, B), although the difference in
staining intensities in Msh2+/2 and Msh2D/2 striata did not
reach statistical significance (p= 0.18).
In ten-month striata we observed a dramatic reduction in the
number of mAb5374-positive intranuclear inclusions in Msh2D/D,
Msh2D/2 and Msh22/2 mice (Figure 4C, D). We were not able
to perform statistical analyses of inclusion number in Msh2D/D or
Msh22/2 mice due to an N=1 for each of these genotypes,
Figure 1. Conditional deletion of the floxed Msh2 allele in the striatum. A. Genotyping for the conditional Msh2 allele in genomic DNA
extracted from striatum of Msh2+/+, Msh2flox/+, Msh2flox/+ D9-Cre and Msh2flox/flox D9-Cre mice. The deleted (D) Msh2 allele is present only in mice
harboring both the Msh2flox allele and the D9-Cre transgene. B. Genotyping for the conditional Msh2 allele in genomic DNA extracted from five
different tissues from a Msh2flox/+ D9-Cre mouse shows that the deletion is specific for the striatum. Mice were six weeks of age. flox: Msh2 allele
flanked by loxP sites; D:deleted Msh2 allele; wt: wild-type Msh2 allele.
doi:10.1371/journal.pone.0044273.g001
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however, quantitative comparison of inclusion number in Msh2D/
2 versus Msh2+/2 striata showed a highly statistically significant
difference (p,0.001). Together, these data indicate that Msh2 is
a critical modifier that acts within MSNs to accelerate CAG repeat
length-dependent mutant huntingtin phenotypes that are reflective
of an ongoing HD-relevant pathogenic process.
Discussion
We have demonstrated that Msh2 acts in MSNs as a genetic
enhancer of both HTT CAG repeat expansion and of HTT
CAG repeat length-dependent mutant huntingtin phenotypes
that occur as a part of an ongoing pathogenic process. As
discussed previously [25], Msh2 could, in principle, modify the
disease process either indirectly via its role in modulating CAG
repeat length, or directly, by some other unknown mechanism.
Our findings indicate that Msh2 does not accelerate the
pathogenic process via detrimental effects to supportive glial
cells or via detrimental systemic effects at the level of the whole
organism, but rather acts in a cell-autonomous manner to
influence phenotypes in MSNs. These data, therefore, are
consistent with an indirect role for Msh2 as a modifier of the
Figure 2. Msh2 protein levels in the striata of Msh2 conditional knockout mice. A. Representative immunoblot of striatal lysates from five-
month HdhQ111/+ mice with Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2 and Msh22/2 genotypes probed with an anti-Msh2 antibody (upper panel).
The membrane was stripped and re-probed with an anti-a-tubulin antibody (lower panel). Arrowhead indicates Msh2 protein. B. Quantification of
immunoblots. The density of Msh2 bands from four immunoblots, each containing striatal protein lysates from different HdhQ111/+ mice with
Msh2+/+ (n = 6, CAG 114, 116, 120, 123, 123, 124), Msh2+/2 (n = 5, CAG 110, 114, 117, 119, 122), Msh2D/D (n = 3, CAG 118, 124, 126), Msh2D/2 (n = 7,
CAG 111, 113, 119, 120, 123, 124, 124), and Msh22/2 (n = 2, CAG 125 and a Hdh+/+mouse) genotypes was quantified with QuantityOne software and
normalized by the density of the corresponding a-tubulin bands. Four protein blots were run; on each, the Msh2/a-tubulin ratio was normalized to
that of Msh2+/+ (100%) on that gel. Normalized Msh2/a-tubulin ratios were averaged across the 4 gels. Bars represent mean 6SD. **p,0.01;
***p,0.001. C. Fluorescent micrographs of striatal sections from five-month HdhQ111/+ mice with Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2 and
Msh22/2 genotypes co-stained with anti-MSH2 ab70270 and anti-DARPP-32 D32-6a antibodies. Note the significant overlap in DARPP-32 and Msh2
signals in Msh2+/+ and Msh2+/2 striata, the loss of specific Msh2 signal in all cells in Msh22/2 striata and the specific loss of Msh2 signal in DARPP-
32-positive cells in Msh2D/D and Msh2D/2 striata. D. Mean integrated intensity of Msh2 immunostaining in DARPP-32-positive cells (total integrated
intensity of ab70270 staining in D32-6a-positive cells normalized by the number of D32-6a-positive cells) in the striatum of the following five-month
mice: Msh2+/+ (n = 6, CAG 113, 118, 119, 121, 123, 125), Msh2+/2 (n = 3, CAG 114, 114, 123), Msh2D/D (n = 4, CAG 121, 121, 126, 129), Msh2D/2 (n = 7,
CAG 113, 121, 121, 122, 125, 125, 133), and Msh22/2 (n = 3, CAG 112, 120, 123). Bars represent mean 6S.D. *** p,0.0001, ** p,0.01, * p,0.05
(Student’s t-test).
doi:10.1371/journal.pone.0044273.g002
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pathogenic process via its effect on the somatic expansion of the
HTT CAG repeat that occurs predominantly in MSNs. Our
data support the hypothesis that somatic HTT CAG expansion
in cells susceptible to the effects of mutant huntingtin accelerates
the disease process, and further indicate that preventing somatic
expansion in MSNs would have therapeutic benefit.
Laser capture microdissection studies in HD postmortem cortex
and striatum have demonstrated that HTT CAG expansions occur
both in neurons and glia, with neurons tending to have the longest
expansions and greatest repeat length heterogeneity [14,16].
Analysis of HTT CAG repeat length in microdissected neuronal
and glial cells from striata of R6/2 HTT exon 1 transgenic mice
supports the association of the most highly expanded repeats with
neuronal cells [16]. Finer microdissection of neuronal populations
within the striatum of knock-in mouse models of HD (Hdh6/Q72
and Hdh4/Q80) demonstrated greater HTT CAG repeat expan-
sion in a pan-neuronal (NeuN-positive) population compared to
a nitric oxide synthase (NOS)-positive subpopulation of inter-
neuron’s [14]. While the NeuN-positive cells served as a good
approximation for MSNs that comprise .90% of striatal neurons
these studies did not unequivocally demonstrate the occurrence of
somatic expansions in MSNs. The present study supports the
above data, and for the first time demonstrates that the bulk of the
somatic expansions that occur in striatum arises in MSNs, and
further demonstrates that these expansions are dependent on
Msh2 expression within these neurons. Additional studies would
be needed to determine whether the small proportion of expanded
alleles that are present in the striata of the conditional knockout
mice (Figure 3) are present in non-MSNs (neurons or glia) or in
MSNs in which the floxed Msh2 allele has failed to recombine.
Regardless, it is clear that at a relatively early time-point (five to
ten months of age), MSNs are the major cell type in the striatum
exhibiting somatic expansions, while over time, it appears that
expansions accumulate in other neurons and in glia [14,16]. The
finding that the earliest somatic expansions occur in the neuronal
cell type that is selectively vulnerable in the disease is significant,
supporting the proposition [33] that hyper-expansion of the HTT
CAG repeat in MSNs contributes to their selective demise, and
further suggesting that in HTT CAG mutation carriers, this is
a process that may begin within months of birth.
Why are MSNs particularly vulnerable to repeat expansion?
Several lines of evidence strongly indicate that instability in these
neurons does not arise downstream of the pathogenic process:
firstly, the spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3)
CAG repeats [19,20] and the myotonic dystrophy type 1 (DMPK)
CTG repeat [18] show high levels of striatal instability despite the
striatum being largely unaffected in these diseases; secondly,
accelerating the pathogenic process in HdhQ111 mice does not
increase striatal HTT CAG instability [21]; thirdly, bioinformatic
approaches based on correlating instability with global gene
expression signatures predict the presence of a cellular environ-
ment permissive for repeat instability that is intrinsic to wild-type
striata [21]. Although acute overexpression of polyglutamine-
containing proteins has been found to influence repeat instability
in fly models [34], the overwhelming evidence in accurate genetic
HD disease models expressing mutant huntingtin at physiologi-
cally relevant levels is that factors other than the pathogenic
process itself are primarily responsible for the somatic expansions
that occur in MSNs.
Obvious factors that might underlie this cell-type specificity are
Msh2 itself and its binding partner Msh3 that is also critical for
striatal HTT CAG expansion [25,26,35,36]. However, neither
Msh2 nor Msh3 mRNA or protein levels showed any clear
correlation with HTT CAG instability across tissues that vary in
their degree of overall instability [21], although higher Msh3
protein in striatal neurons versus glia has been suggested [16].
Further investigation of the expression level, sub-cellular localiza-
tion and activities of these proteins in MSNs versus striatal
interneurons and glia is warranted. The stoichiometry of base
excision repair proteins differs in striatum and cerebellum [37] and
may contribute to the sensitivity of MSNs to somatic HTT CAG
expansion. Interestingly, Xpa, a protein critical for transcription-
coupled nucleotide excision repair (TC-NER), is required for
instability of the SCA1 CAG repeat in brain, but not in peripheral
tissues [38]. It would be of interest to determine whether Xpa and
TC-NER might play a role in contributing to the MSN-selective
instability of the HTT CAG repeat. Transcription has also been
shown to contribute to CAG/CTG instability [39–42]. Although
steady state levels of HTT sense or antisense transcript do not
clearly correlate with levels of tissue instability [43], it is possible
that rates of sense, antisense or convergent transcription could play
a role in determining the cell-type specificity of somatic instability
in HD. Unbiased genome-wide analyses of factors associated with
somatic instability, however, suggest that a combination of many
factors is likely to contribute to the propensity of a particular tissue
or cell-type towards somatic expansion [21].
In summary, the susceptibility of MSNs to both HTT CAG
instability and HD pathogenesis strongly indicates that somatic
expansion is relevant to the disease process in these neurons.
Further experiments are required to unequivocally establish
a role for somatic expansion as a disease modifier, to assess the
spectrum of disease phenotypes that are subject to modification
by somatic expansion as well as the extent to which they are
modified. The prediction is that phenotypes that are CAG
repeat length-dependent would be accelerated to some degree
by further somatic expansion. Ongoing experiments are aimed
at identifying CAG repeat length dependent phenotypes that
will provide additional logical endpoints with which to test the
hypothesis that somatic expansion accelerates the pathogenic
process in mice.
How might somatic expansion be prevented in patients? In
general, eliminating MMR proteins as a therapeutic strategy is
undesirable due to the potential for tumor development, although
targeting to the brain would likely reduce the tumor potential as
cell-types in the periphery are the most susceptible to the somatic
loss of MMR proteins. However, understanding the mechanism by
which MMR proteins result in CAG expansion may provide
a means to specifically intervene in this process without interfering
Figure 3. Deletion of Msh2 in medium-spiny striatal neurons eliminates the majority of striatal HTT CAG expansions. GeneMapper
traces of PCR-amplified HTT CAG repeats from striatum, cortex, liver and tail DNA of representative five-month HdhQ111/+ mice (A) or from striatum
and tail of representative ten month HdhQ111/+ mice (C) with Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2 and Msh22/2 genotypes. Constitutive CAG
repeat lengths, as determined in tail DNA, are indicated. Instability indices were quantified from GeneMapper traces of PCR-amplified HTT CAG
repeats from five-month striatum, cortex and liver (B) and ten-month striatum (D) of HdhQ111/+ mice with Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2
and Msh22/2genotypes. Five-month mice: Msh2+/+ (n = 6, CAG 113, 118, 119, 121, 123, 125), Msh2+/2 (n = 4, CAG 114, 114, 120, 123), Msh2D/
D(n = 5, CAG 113, 121, 121, 126, 129), Msh2D/2(n = 7, CAG 113, 121, 121, 122, 125, 125, 133) and Msh22/2 (n = 3, CAG 112, 120, 123). Ten-month
mice: Msh2+/+ (n = 6, CAG 118, 121, 121, 123, 126, 134), Msh2+/2 (n = 4, CAG 116, 118, 123, 131), Msh2D/D (n = 1, CAG 133), Msh2D/2 (n = 7, CAG 115,
115, 117, 120, 121, 122, 123) and Msh22/2 (n = 1, CAG 132). Bars represent mean 6 S.D. *** p,0.0001, * p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0044273.g003
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in the role of these proteins in global genome maintenance.
Alternative approaches could include the direct targeting of
nucleic acid metabolic intermediates that occur during the
expansion process, as recently indicated for the DMPK CTG
repeat [44]. Finally, identification of additional factors that
underlie HTT CAG instability in MSNs is an important goal as
this would likely lead to novel targets for reducing somatic
expansion in this vulnerable cell population.
Figure 4. Deletion of Msh2 in medium-spiny neurons delays nuclear huntingtin phenotypes. A, B. Nuclear mutant huntingtin
immunostaining is decreased in the striata of five-month old HdhQ111/+ mice with deletion of Msh2 in MSNs. A. Fluorescent micrographs of striata
double-stained with anti-huntingtin mAb5374 and anti-histone H3 antibodies for three CAG repeat length-matched mice (Msh2+/+ CAG 113, Msh2D/
D CAG 112, Msh22/2 CAG 113). B. Box plot showing upper and lower quartiles, median and range for the normalized mAb5374 immunostaining
intensity (total mAb5374 staining intensity normalized to the number of H3-positive nuclei). Outlier (circle) is defined by a standard interquartile
method and is included in the analysis. Multiple regression analysis was used to determine the effect of Msh2 genotype on mAb5374 staining using
normalized mAb5374 intensity (continuous variable) as a dependent variable and Msh2 genotype (discrete variable), constitutive CAG length
(continuous variable) and position (medial versus lateral, discrete variable) as independent variables. Both constitutive CAG length (P,0.05) and
medial versus lateral position (P,0.001) were significantly associated with normalized mAb5374 intensity. Asterisks above the bars indicate
a significant difference from Msh2+/+ at a p-value cut-off of p,0.05(*), p,0.01 (**), p,0.001 (***) in the regression analysis. Msh2D/2 was not
significantly different from Msh2+/2 (p = 0.18). The five-month mice used in the quantitative analysis are as follows: Msh2+/+ (n = 6, CAG 113, 118,
119, 121, 123, 125), Msh2+/2 (n = 4, CAG 114, 114, 120, 123), Msh2D/D (n = 5, CAG 113, 121, 121, 126, 129), Msh2D/2 (n = 7, CAG 113, 121, 121, 122,
125, 125, 133) and Msh22/2 (n = 3, CAG 112, 120, 123). Note that the relatively ‘‘weak’’ effect of the Msh22/2 genotype likely reflects the small
number of mice of this genotype and hence the least accurate estimate of the relationship of mAb5374 intensity to CAG length in the regression
analysis. C, D. Intranuclear inclusions are decreased in the striata of ten-month old HdhQ111/+ mice with deletion of Msh2 in MSNs. C. Fluorescent
micrographs of striata stained with mAb5374 from mice with Msh2+/+ (CAG 121), Msh2+/2 (CAG 123), Msh2D/D (CAG 133), Msh2D/2 (CAG 123) and
Msh22/2 (CAG 132) genotypes. D. Quantification of the percentage of cells containing an inclusion (more than one inclusion per cell was rarely
observed). The total number of cells was determined by co-staining with histone H3 (not shown). The ten-month mice used in the quantitative
analysis are as follows: Msh2+/+ (n = 6, CAG 118, 121, 121, 123, 126, 134), Msh2+/2 (n = 4, CAG 116, 118, 123, 131), Msh2D/D (n = 1, CAG 133), Msh2D/
2 (n = 7, CAG 115, 115, 117, 120, 121, 122, 123) and Msh22/2 (n = 1, CAG 132). Bars represent mean 6S.D.
doi:10.1371/journal.pone.0044273.g004
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Materials and Methods
Mice
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health under an approved protocol of
the Massachusetts General Hospital Subcommittee on Research
Animal Care (protocol number 2009N000216). HdhQ111 knock-in
mice used in this study were on a C57BL/6J background [24] and
were maintained by breeding heterozygous males to C57BL/6J
wild-type mice from The Jackson Laboratories. The actual repeat
size of the mice used in this study ranged from 110 to 134 CAGs.
All analyses were performed on heterozygous HdhQ111/+ mice.
D9-Cre transgenic mice contain a genomic fragment, comprising
,2 kb of 59 regulatory sequence, the endogenous ATG, and the
introns and exons of the mouse Ppp1r1b gene encoding DARPP-
32, driving the expression of Cre recombinase [28]. These mice
were on a C57BL/6J background and were maintained as
homozygotes. Msh2flox mice [27] that were used in this study
had been backcrossed for nine generations to C57BL/6J.
Constitutional Msh2 null mice (Msh22/2) [45] were on
a C57BL/6N background. Note that we have not observed
differences in HdhQ111 instability or mAb5374 immunostaining
phenotypes on C57BL/6J and C57BL/6N background (not
shown), therefore the mixed C57BL/6J and C57BL/6N back-
ground is unlikely to be a confounding factor in our interpretation
of the results.
To generate the mice of the appropriate genotypes for this
study, HdhQ111/+, Msh2flox/+, Msh2 null and D9-Cre mice were
crossed together to obtain Msh2+/+ mice with two functional
Msh2 alleles, Msh2+/2 mice with a single functional Msh2 allele,
Msh2D/D mice in which both alleles are deleted in MSNs,
Msh2D/2 mice with one constitutionally deleted Msh2 allele and
one Msh2 allele deleted in MSNs, and Msh22/2 mice with two
constitutionally deleted Msh2 alleles. All of the mice analyzed for
instability and mutant huntingtin phenotypes with these genotypes
were HdhQ111/+ heterozygotes. A detailed schematic of the
crosses involved is shown in Figure S1.
Genotyping and Analysis of Somatic Instability
Genomic DNA was isolated from tail biopsies at weaning for
routine genotyping analysis or from adult tissues (either fresh or
fixed) for somatic instability analysis, using the PureGene DNA
isolation kit (Gentra, Minneapolis, MN, USA). Genotyping of the
HdhQ111 knock-in allele was carried out as described previously
[26]. Msh2flox and D9-Cre mice were genotyped as described
[27,28]. Msh2 null mice [45] were genotyped in a three-primer
PCR assay using 1 mM primer MSH2A.
(59 CCCTCCTGTTGAGCCATCTTA), 0.75 mM of primer
MSH2B (59 GCCAGCTCATTCCTCCACTC) and 0.5 mM of
primer MSH2C (59 TTCGCTGCTTGTCTCTGGAAT),
200 mM dNTPs, 1 x Qiagen PCR buffer with 1.5 mM MgCl2
and 0.6 units of Taq polymerase (Qiagen). Cycling conditions were
95uC for 9 mins; 40 cycles of 94uC for 45 sec, 56uC for 45 sec,
72uC for 45 sec; 72uC for 5 mins, generating a 188 bp product
from the wild-type allele (MSHA/MSHC primers) and a 300 bp
product from the Msh2 null allele (MSH2B/MSH2C primers).
HdhQ111 CAG repeat size was determined using human HTT
CAG-specific primers as previously described [26] with the
forward primer fluorescently labeled with 6-FAM (Perkin Elmer).
Products were resolved using the AB13730xl automated DNA
analyzer (Applied Biosystems). GeneMapper v3.7 with GeneScan
500-LIZ as internal size standard was used to assign repeat size,
defined as the highest peak in the GeneMapper trace. All runs
included the same control DNAs of known HTT CAG repeat size.
Somatic instability was quantified from the GeneMapper traces as
described previously [21]. Briefly, GeneMapper peaks ,10% of
the height of the highest peak were excluded. For peaks exceeding
the 10% background threshold, normalized peak heights were
calculated by dividing the peak height by the sum of all peak
heights over background. The change in CAG length of each peak
from the highest peak in tail DNA (main allele) was determined,
the normalized peak height was multiplied by the CAG change
from the main allele, and these values were summed to generate
an instability index that represents the mean CAG repeat length
change in the population of cells being analyzed.
Immunohistochemistry
Primary antibodies were: mouse monoclonal anti-huntingtin
mAb5374 (Chemicon), and rabbit polyclonal anti-histone H3
(Abcam ab1791), rabbit polyclonal anti-MSH2 (Abcam ab70270)
and mouse monoclonal anti-DARPP-32 (D32-6a; a kind gift from
Dr. Angus Nairn). Immunostaining was performed on 7 mm
coronal sections of periodate-lysine-paraformaldehyde (PLP)-per-
fused and -post-fixed, paraffin-embedded brains. Perfusion and
tissue processing/embedding methods have been described pre-
viously [30]. One hemisphere of the brain was embedded for
sectioning and the other was used for dissection of striatum, cortex
and cerebellum for analysis of somatic instability. Sections chosen
for immunostaining were aligned with respect to their anterior/
posterior location in the brain. The sections were deparaffinized,
rehydrated and subjected to heat-mediated epitope retrieval (Na-
citrate buffer pH 6.0) followed by quenching of endogenous
peroxidase with 0.3% H2O2/methanol for 30 min at room
temperature and blocked in 3% normal horse serum (NHS) in
TBS for 1h at room temperature.
For detection of diffusely immunostaining nuclear huntingtin,
incubation with mAb5374 (1:100 in 1% NHS/TBS) was carried
out overnight at 4uC. mAb5374 signal was then amplified using
the TSA Biotin System (Perkin Elmer) according to manufac-
turer’s instructions. Briefly, sections were incubated sequentially
with biotinylated anti-mouse IgG (Vectastain Elite ABC kit;
Vector Laboratories) at 1:200 dilution in 1% NHS/TBS for 1 h
at RT, with Streptavidin-conjugated horseradish peroxidase
(Streptavidin-HRP, TSA Biotin System, Perkin Elmer) at 1:100
in 1% NHS/TBS for 30 min at RT, and with biotinylated
Tyramide Amplification reagent (TSA Biotin System, Perkin
Elmer) at 1:75 in the diluent provided for 20 min at RT.
mAb5374 staining was detected by Streptavidin-Alexa Fluor 488
(Invitrogen) at 1:500 in 1% NHS/TBS for 1 h at RT. For
double staining with mAb5374/anti-histone H3 antibody,
sections were incubated with both primary antibodies overnight
at 4uC, and histone H3 staining was detected with donkey anti-
rabbit Alexa Fluor 546-conjugated secondary antibody (Invitro-
gen, 1:1000) added together with Streptavidin-Alexa Fluor 488.
For detection of huntingtin inclusions, sections were incubated
with mAb5374 (1:200 in 1% NHS/TBS) overnight at 4uC.
Signal was detected using goat anti-mouse-HRP (TSA kit #2,
Invitrogen) at 1:50 in 1% NHS/TBS for 1 h at RT, followed
by Alexa Fluor 488-conjugated Tyramide (TSA kit #2,
Invitrogen) at 1:100 in the diluent provided with the TSA kit
#2, for 25 min at RT. Detailed conditions were according to
manufacturer’s instructions (TSA kit #2, Invitrogen). For
double staining with mAb5374/anti-histone H3 antibody,
sections were incubated with both primary antibodies overnight
at 4uC, and histone H3 staining was detected with donkey anti-
rabbit Alexa Fluor 546-conjugated secondary antibody (Invitro-
gen, 1:1000) added after Tyramide-Alexa Fluor 488. For double
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staining with anti-DARPP-32/anti-Msh2 antibodies, sections
were incubated with both primary antibodies (D32-6a at
1:200 and ab70270 at 1:500 in 1%NHS/TBS) overnight at
4uC, followed by sequential amplification of Msh2 and DARPP-
32 signal. First, Msh2 signal was amplified using the TSA Biotin
System, and quenching of HRP activity (0.1% sodium azide/
0.3% H2O2 in TBS for 30 min at RT) was performed before
the final addition of streptavidin-Alexa Fluor 555. Then,
DARPP-32 signal was amplified by incubating with goat anti-
mouse-HRP (TSA kit #2, Invitrogen) at 1:100 and Tyramide-
Alexa Fluor-488 (TSA kit #2, Invitrogen) at 1:100 in the
diluent provided with the TSA kit #2, for 25 min at RT.
Detailed conditions were according to manufacturer’s instruc-
tions (TSA kit #2, Invitrogen). ‘No primary antibody’ and
‘single primary antibody’ control experiments demonstrated the
specificity of the Alexa Fluor-555 and Alexa Fluor-488 signals
for Msh2 and DARPP-32, respectively.
Sections were mounted in ProLong Gold antifade reagent
(Invitrogen). Fluorescent microscopy was performed with a Zeiss
Axioskop 2 microscope equipped with AxioCamMRm camera
and AxioVision 4.6 image acquisition software, using Plan
Apochromat 20x/0.8 M27 or Plan Neofluar 40x/0.75 Ph2
objectives. Images that were to be quantified and compared were
taken with the same exposure times.
Quantification of Immunohistochemical Data
Cell Profiler 2.0 r10997 cell image analysis software was used
for quantification of mAb5374 and Msh2 immunostaining in-
tensity. Four micrographs were taken from each mouse (one from
medial and one from lateral striatum in two consecutive sections
located on the same slide), each micrograph representing an area
of 2206170 mm. Total (integrated) intensity of mAb5374 staining
was measured in all mAb5374-positive nuclei in each area and
normalized by the total number of nuclei (as determined by the
number of all histone H3-positive nuclei) in the same area. The
resulting value, representing the mean intensity of mAb5374
staining per nucleus, was averaged for each mouse (for medial and
lateral striatal areas separately as well as for all four striatal areas).
Note that there was some variation in histone H3 intensity both
within and between mice (see for example Figure 4). However, this
did not vary systematically with genotype, nor did it correlate with
the number of histone H3-positive nuclei. We normalized against
the number of histone H3-postive nuclei in order to control for
potential differences in cell density in different coronal sections,
However, the number of histone H3-positive nuclei between
sections analyzed did not vary considerably, indicating that our
sections were reasonably well matched in terms of their anterior/
posterior positions. For Msh2 staining, total (integrated) intensity
of Msh2 staining was measured in DARPP-32-positive cells in
each area and normalized by the number of DARPP-32-positive
cells. The resulting value, representing the intensity of Msh2
staining per MSN, was averaged for each mouse (from the four
striatal areas as described above). The number of nuclear
huntingtin inclusions in the striatum of 10 month old mice was
quantified in fluorescent micrographs of mAb5374/anti-H3-
stained striatal sections (four 4356435 mm striatal areas per
mouse, as described above) using ImageJ software and normalized
to the number of H3-positive cells.
Immunoblot Blot Analysis
Striata were homogenized in RIPA buffer supplemented with
5 mM EDTA and protease inhibitors (Halt protease Inhibitor
Cocktail, ThermoScientific) by mechanical grinding with dispos-
able pestle (Fisher Scientific) and further sonication (Branson
sonifier, power level 3.5, two 10-sec pulses on ice). The
homogenates were kept on ice for 30 min and then clarified by
centrifugation for 30 min at 14000 rpm. Protein concentrations
were measures using Bio-Rad DC protein assay kit. Striatal
extracts (30 ug per lane) were resolved by SDS-PAGE in Novex
10% Bis-Tris gels (Innvitrogen). Msh2 protein was detected by
immunoblotting using anti-MSH2 antibody ab70270 (Abcam) at
1:4000 in 5% non-fat milk/TBS/0.1% Tween-20. Alpha-tubulin,
as detected by 1:5000 DM1A (Cell Signaling Technology) in 5%
milk/TBS/0.1% Tween-20, was used as loading control. Quan-
tification was done by measuring the density of Msh2 and a-
tubulin bands with QuantityOne software with subtraction of local
background.
Statistical Analyses
Pairwise comparisons of instability indices, intranuclear inclu-
sions and Msh2 protein levels were determined using a Student’s t-
test (Excel). In these comparisons, Msh2D/D mice were generally
compared to Msh2+/+ mice, and Msh2D/2 mice were compared
to Msh2+/2 mice as this latter comparison provides a more
stringent test of the effect of the conditional deletion on
a background of a single constitutionally deleted Msh2 allele. To
control for the effects of constitutive CAG length and striatal
position (medial versus lateral) in the determination of the effect of
Msh2 genotype on mAb5374 immunostaining intensity multiple
regression analysis was carried out using normalized mAb5374
intensity as the dependent (continuous) variable and Msh2
genotype (discrete variable), constitutive CAG length (continuous
variable) and position (discrete variable) as independent variables
using the R statistical package (version 2.7.2).
Supporting Information
Figure S1 Breeding Scheme. The breeding scheme shows
how we generated HdhQ111/+ mice of the five Msh2 genotypes
(Msh2+/+, Msh2+/2, Msh2D/D, Msh2D/2, Msh22/2) that were
used in this study using the four transgenic/knock-in alleles
(HdhQ111, Msh2 null, Msh2flox, D9-Cre). Breeders in the various
crosses are shaded in green and separated by a green ‘‘X’’. The
genotypes of the resultant mice from these crosses that were
analyzed are indicated in black type. Shown in red type/boxes are
the five Msh2 genotypes using the final terminology we describe
throughout the manuscript. Note that mice with a single functional
Msh2 allele could be generated in a number of ways and were
pooled as heterozygotes (Msh2+/2 mice in red type). Similarly,
mice with two functional Msh2 alleles could be generated in more
than one way and were pooled as wild-types (Msh2+/+ mice in red
type).
(TIF)
Figure S2 Quantitative fluorescent assay to detect the
time-dependent increase in mAb5374-positive nuclear
mutant huntingtin immunostaining in the striata of
HdhQ111/+ mice (C57BL/6J). Left: Fluorescent micrographs
of striata of three Hdh+/+ mice (upper panel) and three CAG
repeat length-matched HdhQ111/+ mice (lower panel), double-
stained with anti-huntingtin mAb5374 and anti-histone H3
antibodies. CAG repeat numbers: 121 (2.3 months), 120 (3.3
months), 121 (5.0 months). Note that this antibody does not stain
huntingtin in wild-type (Hdh+/+) mice. Right: Quantification of
the mAb5374 nuclear immunostain in HdhQ111/+ striata,
normalized to the number of H3-positive nuclei. 2.3 mo N=4;
3.3 mo. N=3; 5.0 mo N=3. Bars are mean6S.D.
(DOCX)
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